Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

INTRODUCTION: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. METHODS: A possible disease-modifying effect of solanezumab was assessed using a new statistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975050/
https://www.ncbi.nlm.nih.gov/pubmed/29854931
http://dx.doi.org/10.1016/j.trci.2015.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975050/
https://www.ncbi.nlm.nih.gov/pubmed/29854931
http://dx.doi.org/10.1016/j.trci.2015.06.006

Ejemplares similares